Cyclic morphiceptin analogs: cyclization studies and opioid activities in vitro

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Peptide Chemistry

Background:

• Opioid peptides like beta-casomorphin-5 and morphiceptin are crucial for pain management.
• Developing analogs with improved opioid activity profiles is a key area of pharmaceutical research.

Purpose of the Study:

• To synthesize cyclic beta-casomorphin-5 analogs with enhanced opioid activity.
• To investigate the influence of ring size and chirality on cyclization yield and opioid receptor binding.

Main Methods:

• Synthesis of tetrapeptide sequences (Boc-Tyr(tBu)-D-Xaa-Phe-Yaa-OH) with varying amino acids (Lys, Orn, A2bu) and proline configurations.
• Cyclization reactions under controlled conditions, followed by purification via crystallization and chromatography.
• Characterization using HPLC, TLC, electrospray mass spectrometry, and 1H-NMR spectroscopy.
• In vitro bioassays (guinea pig ileum and mouse vas deferens) to assess opioid receptor activity.

Main Results:

• Cyclization of precursors with L-proline exclusively yielded cyclodimers.
• Cyclodimerization was favored for the 11-membered ring analog [D-A2bu2, D-Pro4].
• A cyclomonomer/cyclodimer ratio of approximately 80:20 was achieved for [D-Lys2, D-Pro4] and [D-Orn2, D-Pro4] analogs.
• The cyclic monomers [D-Lys2, D-Pro4] and [D-Orn2, D-Pro4] exhibited high opioid activity at mu- and delta-receptors (nM range).
• Cyclodimers showed significantly lower potency (2-3 orders of magnitude less) in both assays.

Conclusions:

• Chirality, specifically the D-configuration of proline, is critical for favoring monomer formation in cyclic opioid peptide analogs.
• The synthesized cyclic monomers possess potent and balanced mu- and delta-opioid receptor activity.
• These findings provide a basis for designing novel opioid-based therapeutics with improved pharmacological profiles.